Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27481442 | 0.94 | SIGMAR1 (0.54) | SIGMAR1MEN1KMT2AHPGDKCNH2 | |
| SCHEMBL28475113 | 0.92 | SIGMAR1 (0.59) | SIGMAR1MEN1KMT2AHPGDKCNH2 | |
| Hydrochloric Acid SCHEMBL10616388 | 0.89 | SIGMAR1 (0.56) | SIGMAR1MEN1KMT2AHPGDKCNH2 | |
| SCHEMBL2911080 | 0.86 | SIGMAR1 (0.56) | SIGMAR1MEN1KMT2AHPGDL3MBTL1 | |
| SCHEMBL22472264 | 0.81 | EPHX2 (0.50) | SIGMAR1MEN1KMT2APOLBHPGD | |
| SCHEMBL28504289 | 0.81 | EPHX2 (0.50) | SIGMAR1MEN1KMT2APOLBHPGD | |
| SCHEMBL8369238 | 0.81 | EPHX2 (0.50) | SIGMAR1MEN1KMT2APOLBHPGD | |
| SCHEMBL8897396 | 0.79 | SIGMAR1 (0.50) | SIGMAR1MEN1KMT2AHPGDL3MBTL1 | |
| SCHEMBL10653567 | 0.79 | SIGMAR1 (0.53) | SIGMAR1L3MBTL1 | |
| SCHEMBL5501337 | 0.79 | ALDH1A1 (0.47) | SIGMAR1MEN1KMT2APOLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7268166-B2 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NPS PHARMACEUTICALS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-7087765-B2 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NPS PHARMACEUTICALS, INC. (US) | 2006-08-08 | — | — | US | disclosed |
| US-20060142594-A1 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | MUELLER ALAN L | 2006-06-29 | — | — | US | disclosed |
| CN-1153568-C | Compounds active at a novel side on receptor-operated calcium channel useful for treatment of neurological disorders | NPSҩ������˾ | 2004-06-16 | — | — | CN | disclosed |
| US-6750244-B2 | NERVOUS SYSTEM DISORDERS | NPS PHARMACEUTICALS, INC. | 2004-06-15 | — | — | US | disclosed |
| EP-1425002-A1 | ARYLOXYPROPYLAMINES AS CHEMOSENSITIZING AGENTS IN THE TREATMENT OF CANCER | Ramot at Tel Aviv University Ltd. (IL) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003022258-A1 | ARYLOXYPROPYLAMINES AS CHEMOSENSITIZING AGENT IN THE TREATMENT OF CANCER | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2003-03-20 | — | — | WO | disclosed |
| US-20020004522-A1 | Nervous system disorders | NPS PHARMACEUTICALS, INC. | 2002-01-10 | — | — | US | disclosed |
| US-6211245-B1 | DRUGS FOR CONTROLLING CALCIUM MODULATORS | NPS PHARMACEUTICALS, INC. | 2001-04-03 | — | — | US | disclosed |
| CN-1192679-A | Compounds active at a novel side on receptor-operated calcium channel useful for treatment of neurological disorders | N P S PHARMACEUTICALS INC (US) | 1998-09-09 | — | — | CN | disclosed |
| EP-0831799-A1 | COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS | NPS PHARMACEUTICALS, INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040097-A1 | COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS | NPS PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0399504-A2 | Aryloxyphenylpropylamines their preparation and use | NOVO NORDISK A/S (DK) | 1990-11-28 | — | — | EP | disclosed |
| EP-0318727-A2 | Aryloxphenylpropylamines and their preparation and use | NOVO NORDISK A/S (DK) | 1989-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142594-A1 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NCS1, ATP2A1, CACNA1D | SIGMAR1 1369/4885MEN1 4690/4885KMT2A 3335/4885 |
| US-20020004522-A1 | Nervous system disorders | HIF1A, PYGB, LDHB | SIGMAR1 3929/4885MEN1 3316/4885KMT2A 1100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.